
Aiforia equips pathologists and scientists in clinical, pre-clinical, and academic labs with powerful deep learning AI and cloud-based technology. Their solutions aim to increase the speed, accuracy, and consistency of analyzing large and complex medical images, particularly in pathology. The company's mission is to transform pathology image analysis with AI, enabling better patient care. Aiforia offers clinical solutions for diagnostic accuracy and productivity, research solutions for pharma, biotech, and academic researchers, and an AI development tool for creating and customizing AI models. Their unique offerings include future-proof AI models, transparent algorithms, ease of use requiring no coding expertise, and robust security adhering to ISO 27001, SOC 2 Type II, ISO 13485, IVDR, GDPR, and HIPAA standards.

Aiforia equips pathologists and scientists in clinical, pre-clinical, and academic labs with powerful deep learning AI and cloud-based technology. Their solutions aim to increase the speed, accuracy, and consistency of analyzing large and complex medical images, particularly in pathology. The company's mission is to transform pathology image analysis with AI, enabling better patient care. Aiforia offers clinical solutions for diagnostic accuracy and productivity, research solutions for pharma, biotech, and academic researchers, and an AI development tool for creating and customizing AI models. Their unique offerings include future-proof AI models, transparent algorithms, ease of use requiring no coding expertise, and robust security adhering to ISO 27001, SOC 2 Type II, ISO 13485, IVDR, GDPR, and HIPAA standards.
Founded: 2013 (spin-off from FIMM, University of Helsinki)
Headquarters: Helsinki, Finland
Product focus: Cloud-based deep learning AI for digital pathology (AI model development and clinical AI suites)
Regulatory / security: Claims CE‑IVD/IVDR-marked clinical solutions and adherence to standards including ISO 27001, SOC 2 Type II, ISO 13485, IVDR, GDPR, HIPAA
Funding: Series B (first tranche €12.6M announced June 2021); total funding reported ≈ $25.24M
Employees: Approximately 81
Digital pathology and medical image analysis for clinical diagnostics and research.
2013
Healthtech / Medical software (digital pathology)
€12.6M
Round may reach €25.2M if second tranche is exercised
“Series B led by Epredia/PHC Holdings with participation from Aktia Nordic Micro Cap and existing shareholders”